GSK to Test-Run Procognia’s Protein Arrays for Kinase-Screening Studies | GenomeWeb
NEW YORK (GenomeWeb News) – Procognia said today that GlaxoSmithKline will use its protein arrays to profile kinase kits in drug development research.
 
Under the agreement, GSK will use Procognia’s protein array technology with its own kinase inhibitors in profiling studies to assess whether it can integrate these arrays into its screening process.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.